
A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.


New data support the “two-hit” hypothesis: early allergic sensitization plus respiratory infections may impair lung function into adulthood, up to age 25 years.

During his New Wave Dermatology interview, Naveed Sami, MD, spoke about additional takeaways from his session on the cutaneous effects of immunotherapies.

Discover key advancements and setbacks in cardiovascular medicine from May 2025, shaping the future of cardiometabolic care and treatment options.

Investigators examined emergency department utilization as a product of age, patient-reported severity of vaso-occlusive episodes, and Social Vulnerability Index score.

Hosts breakdown diabetes technology updates from May 2025 and Breakthrough T1D's push for improved screening.

In this interview at the New Wave Dermatology meeting, Naveed Sami, MD, highlights some of the notable takeaways from his talk on the impacts of immunotherapies.


This May was characterized by HCPLive’s coverage of the ARVO and Envision conferences, as well as a slew of FDA approvals towards the end of the month.

Lyra Therapeutics announced LYR-210 met primary and secondary endpoints in phase 3 ENLIGHTEN 2, improving CRS symptoms and showing strong safety.

Vera Therapeutics intends to bring the results before the FDA by the end of 2025; they anticipate an approval and commercial launch in 2026.

This Month in Review summary includes a list of some of the most notable or impactful news in the dermatology field from May 2025.

Point-of-care intestinal ultrasound offers real-time, noninvasive monitoring for pediatric IBD, enabling faster, personalized treatment decisions in routine care.

Brendon Neuen, MBBS, PhD, discusses 3 late breaking clinical trials being presented at ERA 2025.

Contrary to prior research, this study indicates that combining tumor necrosis factor inhibitors or another biologic with antimetabolites has a better chance of managing inflammation than any individual medication.

This interview from the 2025 New Wave Dermatology Conference features DiRuggiero discussing challenging psoriasis cases and tips for healthcare providers.

Systematic review of 34 randomized trials finds EMDR most effective, though civilians were more likely than veterans to lose their PTSD diagnosis after treatment.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new treatment guidelines, in this week's essential news roundup.

A recent study has indicated that FCH results in better tolerability and medication compliance due to lowered risk of adverse gastrointestinal effects.


The May 30, 2025 SOCS News Update highlights cosmetic concerns among patients with skin of color.

Despite controversy, new data show that even high-risk pediatric patients may benefit from a gradual, supervised reintroduction of milk and egg.

Iron deficient diets can lead to anemia and various other health complications in adulthood.

This summary features a variety of abstracts to be presented at the RAD meeting in June 2025, highlighting new data in atopic dermatitis and the dermatology space in general.

A recent study reveals a significant rise in cardiac deaths at home since the COVID-19 pandemic, highlighting urgent healthcare gaps.

Katherine Dahlsgaard, PhD, and Megan Lewis, MSN, discuss how proximity challenges can reduce medically unnecessary avoidance for patients with food allergy anxiety.

Investigators suggest that semaglutide should be used judiciously in treating type 2 diabetes mellitus, as it poses no real risk of nonarteritic anterior ischemic optic neuropathy.

Gerard Criner, MD, spells out GOLD improvements, from interventions like smoking cessation and pulmonary rehabilitation to the heightened importance of spirometry for diagnosis.

This Q&A interview highlights reductions observed in the use of rilzabrutinib for asthma symptom relief in a recent phase 2 study.